Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators

Journal of Cardiovascular Electrophysiology

Volumn 25, Issue 6, 2014, Pages 609-616

  Francia, Pietro ^a   Adduci, Carmen ^a   Semprini, Lorenzo ^a   Borro, Marina ^b   Ricotta, Agnese ^a   Sensini, Isabella ^a   Santini, Daria ^a   Caprinozzi, Massimo ^a   Balla, Cristina ^a   Simmaco, Maurizio ^b   Volpe, Massimo ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

biomarkers; Galectin 3; heart failure; ICD; osteopontin; sudden death

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; OSTEOPONTIN; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; AGED; BLOOD; FOLLOW UP; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

AGED; BIOLOGICAL MARKERS; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 84901985918     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.12364     Document Type: Article

References (38)

1. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE,: Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999; 20: 447-455.
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D,: Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002; 106: 3068-3072.
3. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC,: Survival of patients with a new diagnosis of heart failure: A population based study. Heart 2000; 83: 505-510.
4. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Riegel B, Tarkington LG, Yancy CW,: ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51: e1-e62.
5. Wu TJ, Ong JJ, Hwang C, Lee JJ, Fishbein MC, Czer L, Trento A, Blanche C, Kass RM, Mandel WJ, Karagueuzian HS, Chen PS,: Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: Role of increased fibrosis in the generation of reentry. J Am Coll Cardiol 1998; 32: 187-196.
6. Okamoto H, Imanaka-Yoshida K,: Matricellular proteins: New molecular targets to prevent heart failure. Cardiovasc Therap 2012; 30: e198-e209.
7. Francia P, Uccellini A, Frattari A, Modestino A, Ricotta A, Balla C, Scialla L, Volpe M,: Extracellular matrix remodelling in myocardial hypertrophy and failure: Focus on osteopontin. High Blood Press Cardiovasc Prev 2009; 16: 195-199.
8. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R,: Osteopontin expression is required for myofibroblast differentiation. Circulation Research 2008; 102: 319-327.
9. Dumic J, Dabelic S, Flogel M,: Galectin-3: An open-ended story. Biochimica et Biophysica Acta 2006; 1760: 616-635.
10. Yang RY, Rabinovich GA, Liu FT,: Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10: e17.
11. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM,: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-3128.
12. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, Giannitsis E, Katus HA, Frey N,: Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart failure 2008; 1: 43-49.
13. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ,: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99: 323-328.
14. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ,: Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-68.
15. Okamoto H,: Osteopontin and cardiovascular system. Mol Cellular Biochem 2007; 300: 1-7.
16. Francia P, Balla C, Uccellini A, Cappato R,: Arrhythmia detection in single- and dual-chamber implantable cardioverter defibrillators: The more leads, the better? J Cardiovasc Electrophysiol 2009; 20: 1077-1082.
17. Scatena M, Liaw L, Giachelli CM,: Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2302-2309.
18. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D,: Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012; 60: 1249-1256.
19. Okyay K, Tavil Y, Sahinarslan A, Tacoy G, Turfan M, Sen N, Gurbahar O, Boyaci B, Yalcin R, Demirkan D, Cengel A,: Plasma osteopontin levels in prediction of prognosis in acute myocardial infarction. Acta cardiologica 2011; 66: 197-202.
20. Mayr A, Klug G, Mair J, Streil K, Harrasser B, Feistritzer HJ, Jaschke W, Schocke M, Pachinger O, Metzler B,: Galectin-3: Relation to infarct scar and left ventricular function after myocardial infarction. Int J Cardiol 2013; 163: 335-337.
21. Weir RA, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, McInnes IB, Squire IB, Ng LL, Dargie HJ, McMurray JJ,: Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Failure 2013; 6: 492-498.
22. Arnlov J, Evans JC, Benjamin EJ, Larson MG, Levy D, Sutherland P, Siwik DA, Wang TJ, Colucci WS, Vasan RS,: Clinical and echocardiographic correlates of plasma osteopontin in the community: The Framingham Heart Study. Heart 2006; 92: 1514-1515.
23. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL,: Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108: 385-390.
24. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL,: Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Failure 2010; 12: 826-832.
25. Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R, Wang L, Chen Q, Fukuda K, Shen W,: Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2010; 9: 71-78.
26. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T,: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172: 288-298.
27. Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Elena Rao MA, Trimarco B, Condorelli M,: Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: A 15-year prospective follow-up study. Clin Cardiol 2010; 33: 700-707.
28. Tapanainen JM, Lindgren KS, Makikallio TH, Vuolteenaho O, Leppaluoto J, Huikuri HV,: Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004; 43: 757-763.
29. Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, Marrouche NF, Almahammed S, Wazni OM, Duggal S, Zuzek R, Yamaji H, Cummings J, Chung MK, Tchou PJ, Natale A,: Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006; 92: 190-195.
30. Havmoller R, Chugh SS,: Plasma biomarkers for prediction of sudden cardiac death: Another piece of the risk stratification puzzle ? Circ Arrhythmia Electrophysiol 2012; 5: 237-243.
31. Kanoupakis EM, Manios EG, Kallergis EM, Mavrakis HE, Goudis CA, Saloustros IG, Milathianaki ME, Chlouverakis GI, Vardas PE,: Serum markers of collagen turnover predict future shocks in implantable cardioverter- defibrillator recipients with dilated cardiomyopathy on optimal treatment. J Am Coll Cardiol 2010; 55: 2753-2759.
32. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T,: Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Nat Acad Sci USA 2006; 103: 5060-5065.
33. Heimer R, Bashey RI, Kyle J, Jimenez SA,: TGF-beta modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. J Mol Cell Cardiol 1995; 27: 2191-2198.
34. Behnes M, Brueckmann M, Lang S, Espeter F, Weiss C, Neumaier M, Ahmad-Nejad P, Borggrefe M, Hoffmann U,: Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure. Eur J Heart Fail 2013; 15: 1390-1400.
35. Lok DJ, Klip IT, Lok SI, Bruggink-Andre de la, Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P,: Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in Patients with advanced Chronic heart failure. Am J Cardiol 2013; 112: 831-837.
36. Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, Mehurg SM, Spinale FG,: Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Failure 2011; 4: 246-256.
37. Rosenberg M, Meyer FJ, Gruenig E, Lutz M, Lossnitzer D, Wipplinger R, Katus HA, Frey N,: Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. Eur J Clin Invest 2012; 42: 933-942.
38. Francia P, Balla C, Ricotta A, Uccellini A, Frattari A, Modestino A, Borro M, Simmaco M, Salvati A, De Biase L, Volpe M,: Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol 2011; 153: 306-310.